Skip to main content

Table 2 Information from the nineteen included articles about non-NIP vaccine coverage barriers

From: The coverage and challenges of increasing uptake of non-National Immunization Program vaccines in China: a scoping review

Authors and affiliations

Publication year

Methods and vaccine type

Study sites

Sample size

Access

Affordability

Awareness

Acceptance

Activation

Capacity of the service provider

Ease of access to services

Place of residency

Supply of vaccines

Vaccine price

Government subsidy

Vaccine awareness

Vaccine safety and efficacy

Perceived susceptibility of being infected

Personal health beliefs

Interpersonal and media influence

Effective interventions

Hou et al. [43]c

2014

Stratified sampling survey e

3 provinces

1924 respondents

    

√

√

√

√

√

√

√

 

Chang et al. [44]c

2019

Multistage stratified random sampling survey d

3 provinces

1791 households

√

√

√

 

√

  

√

  

√

 

Deng et al. [45]c

2021

Convenience sampling surveyf

4 PLADs

1022 participants

    

√

 

√

√

√

 

√

 

Wang et al. [46]c

2021

Proportional sampling survey d

31 PLADs

7318 respondents

      

√

√

√

√

√

 

Si et al. [47]c

2021

Stratified sampling survey f

7 PLADs

3867 students

   

√

√

 

√

√

√

√

√

 

Lai et al. [48]c

2022

Multi-stage stratified sampling e

10 PLADs

1138 healthcare workers, 2973 older adults aged ≥ 65

      

√

√

 

√

√

 

Yin et al. [49]c

2023

Multi-stage sampling survey f

31 PLADs

5959 respondents

  

√

 

√

 

√

√

√

√

√

 

Duan et al. [50]a

2016

Commentaryd

  

√

 

√

 

√

√

 

√

√

 

Zhang et al. [51]b

2018

Commentaryd

 

√

√

√

√

√

√

√

√

√

√

 

Wang et al. [52]a

2020

Commentaryd

 

√

√

√

√

√

√

√

√

√

√

 

Wang et al. [53]c

2020

Commentaryd

    

√

 

√

√

   

√

Wang et al. [54]a

2021

Commentaryf

√

  

√

√

 

√

√

√

 

√

 

Wang et al. [55]b

2022

Commentaryd

√

√

 

√

 

√

√

√

  

√

 

Wang et al. [56]c

2020

Systematic reviewd

58 papers

      

√

√

√

√

√

 

Bai et al. [57]b

2022

Narrative reviewe

  

√

 

√

 

√

√

√

 

√

 

Wang et al. [58]c

2022

Systematic reviewf

73 papers

    

√

 

√

√

√

   

Gong et al. [59]c

2021

Qualitative interviewd

3 provinces

26 vaccination providers&160 caregivers

√

√

          

Lin et al. [60]c

2022

Qualitative interviewd

3 provinces

26 interviewees

√

 

√

√

√

 

√

√

  

√

√

Han et al. [61]c

2022

Multi-stage sampling survey and qualitative interviewd

3 provinces

555 for the survey and 49 for the interview

√

  

√

√

       
  1. NIP National Immunization Program; PLADs Provincial-level administrative divisions; PCV Pneumococcal conjugate vaccine; NA not applicable
  2. aFirst author affiliation: China CDC
  3. bFirst author affiliation: Provincial and municipal CDC
  4. cFirst author affiliation: University
  5. dVaccine type: non-NIP vaccine
  6. eVaccine type: PCV vaccine
  7. fVaccine type: HPV vaccine